- About
- Strategic Plan
- Structure
- Governance
- Scientific divisions
- ACRF Cancer Biology and Stem Cells
- ACRF Chemical Biology
- Advanced Technology and Biology
- Bioinformatics
- Blood Cells and Blood Cancer
- Clinical Translation
- Epigenetics and Development
- Immunology
- Infectious Diseases and Immune Defence
- Inflammation
- Personalised Oncology
- Population Health and Immunity
- Structural Biology
- Ubiquitin Signalling
- Laboratory operations
- Funding
- Annual reports
- Human research ethics
- Scientific integrity
- Institute life
- Career opportunities
- Business Development
- Partnering opportunities
- A complete cure for HBV
- A stable efficacious Toxoplasma vaccine
- Activating SMCHD1 to treat FSHD
- Fut8 Sugar coating immuno oncology
- Improving vision outcomes in retinal detachment
- Intercepting inflammation with RIPK2 inhibitors
- Novel inhibitors for the treatment of lupus
- Novel malaria vaccine
- Novel therapy for drug-resistant cancers
- Precision epigenetics silencing SMCHD1 to treat Prader Willi Syndrome
- Rethinking CD52 a therapy for autoimmune disease
- Selective JAK inhibition: mimicking SOCS activity
- Targeting minor class splicing
- Treating Epstein-Barr virus associated malignancies
- Royalties distribution
- Start-up companies
- Partnering opportunities
- Collaborators
- Publications repository
- Awards
- Discoveries
- Centenary 2015
- History
- Contact us
- Research
- Diseases
- Cancer
- Development and ageing
- Immune health and infection
- Research fields
- Research technologies
- People
- Anne-Laure Puaux
- Associate Professor Aaron Jex
- Associate Professor Alyssa Barry
- Associate Professor Andrew Webb
- Associate Professor Anne Voss
- Associate Professor Chris Tonkin
- Associate Professor Daniel Gray
- Associate Professor Edwin Hawkins
- Associate Professor Emma Josefsson
- Associate Professor Ethan Goddard-Borger
- Associate Professor Grant Dewson
- Associate Professor Isabelle Lucet
- Associate Professor James Murphy
- Associate Professor Jeanne Tie
- Associate Professor Jeff Babon
- Associate Professor Joan Heath
- Associate Professor Justin Boddey
- Associate Professor Marco Herold Marco Herold
- Associate Professor Marie-Liesse Asselin-Labat
- Associate Professor Matthew Ritchie
- Associate Professor Melissa Davis
- Associate Professor Oliver Sieber
- Associate Professor Peter Czabotar
- Associate Professor Rachel Wong
- Associate Professor Rhys Allan
- Associate Professor Ruth Kluck
- Associate Professor Sandra Nicholson
- Associate Professor Seth Masters
- Associate Professor Sumitra Ananda
- Associate Professor Tim Thomas
- Associate Professor Wai-Hong Tham
- Associate Professor Wei Shi
- Catherine Parker
- Chela Niall
- Deborah Carr
- Dr Anna Coussens
- Dr Ashley Ng
- Dr Ben Tran
- Dr Bernhard Lechtenberg
- Dr Bob Anderson
- Dr Brad Sleebs
- Dr Diana Hansen
- Dr Drew Berry
- Dr Gemma Kelly
- Dr Gwo Yaw Ho
- Dr Hui-Li Wong
- Dr Ian Majewski
- Dr Jacqui Gulbis
- Dr James Vince
- Dr Joanna Groom
- Dr John Wentworth
- Dr Kate Sutherland
- Dr Kelly Rogers
- Dr Leanne Robinson
- Dr Leigh Coultas
- Dr Lucy Gately
- Dr Margaret Lee
- Dr Mary Ann Anderson
- Dr Maryam Rashidi
- Dr Matthew Call
- Dr Melissa Call
- Dr Misty Jenkins
- Dr Philippe Bouillet
- Dr Rebecca Feltham
- Dr Samir Taoudi
- Dr Sant-Rayn Pasricha
- Dr Shalin Naik
- Dr Sheau Wen Lok
- Dr Simon Chatfield
- Dr Stephen Wilcox
- Dr Tracy Putoczki
- Guillaume Lessene
- Helene Martin
- Joh Kirby
- Keely Bumsted O'Brien
- Mr Joel Chibert
- Mr Simon Monard
- Mr Steve Droste
- Ms Carolyn MacDonald
- Professor Alan Cowman
- Professor Andreas Strasser
- Professor Andrew Lew
- Professor Andrew Roberts
- Professor Clare Scott
- Professor David Huang
- Professor David Komander
- Professor David Vaux
- Professor Doug Hilton
- Professor Gabrielle Belz
- Professor Geoff Lindeman
- Professor Gordon Smyth
- Professor Ian Wicks
- Professor Ivo Mueller
- Professor Jane Visvader
- Professor Jason Tye-Din
- Professor Jerry Adams
- Professor John Silke
- Professor Ken Shortman
- Professor Leonard C Harrison
- Professor Lynn Corcoran
- Professor Marc Pellegrini
- Professor Marnie Blewitt
- Professor Melanie Bahlo
- Professor Mike Lawrence
- Professor Nicos Nicola
- Professor Peter Colman
- Professor Peter Gibbs
- Professor Phil Hodgkin
- Professor Stephen Nutt
- Professor Suzanne Cory
- Professor Terry Speed
- Professor Tony Burgess
- Professor Tony Papenfuss
- Professor Warren Alexander
- Diseases
- Education
- PhD
- Honours
- Masters
- Undergraduate
- Student research projects
- 6 cysteine proteins key mediators between malaria parasites and human host
- A balancing act of immunity: autoimmunity versus malignancies
- Activating https://www.wehi.edu.au/node/add/individual-student-research-page#Parkin to treat Parkinson’s disease
- Analysing single cell technologies to understand breast cancer
- Bioinformatics methods for detecting and making sense of somatic genomic rearrangements
- Characterising new regulators in inflammatory signalling pathways
- Computational melanoma genomics
- Control of human lymphocyte cell expansion in complex immune diseases
- Deciphering biophysical changes in red blood cell membrane during malaria parasite infection
- Deciphering the signalling functions of pseudokinases
- Deep profiling of blood cancers during targeted therapy
- Determining the mechanism of type I cytokine receptor triggering
- Differential expression analysis of RNA-seq using multivariate variance modelling
- Discovering new genetic causes of primary antibody deficiencies
- Discovery of novel drug combinations for the treatment of bowel cancer
- Drug targets and compounds that block growth of malaria parasites
- Effects of nutrition on immunity and infection in Asia and Africa
- Enabling deubiquitinase drug discovery
- Epigenetic drivers of immune cell function
- Epigenetic regulation of systemic iron homeostasis
- Essential role of glycobiology in malaria parasites
- Exploiting cell death pathways in regulatory T cells for cancer immunotherapy
- Fatal attraction: how apoptotic pore assembly is governed during mitochondrial cell death
- Genomic instability and the immune microenvironment in lung cancer
- How do T lymphocytes decide their fate?
- How the epigenetic regulator SMCHD1 works and how to target it to treat disease
- Human lung protective immunity to tuberculosis: host-environment systems biology
- Human monoclonal antibodies against malaria infection
- Identifying novel treatment options for ovarian carcinosarcoma
- Inflammasome activation in autoinflammatory disease
- Investigating mechanisms of cell death and survival using zebrafish
- Investigating microbial natural products with anti-protozoal activity
- Investigating the role of mutant p53 in cancer
- Investigating the role of platelets in motor neuron disease
- Mapping DNA repair networks in cancer
- Molecular mechanisms controlling embryonic lung progenitor cells
- Nanobodies against malaria
- Neutrophil heterogeneity in inflammation
- New approaches to treat cancer and inflammatory disease using the ubiquitin system
- Next generation CRISPR screens using iPSC
- Novel cell death and inflammatory modulators in lupus
- Programming T cells to defend against infections
- Restraining cytokine-receptor signalling in myeloproliferative neoplasms
- Screening for regulators of jumping genes
- Statistical analysis of genome-wide chromatin organisation using Hi-C
- Statistical analysis of trapped-ion-mobility time-of-flight mass spectrometry proteomics data
- Structure and function of E3 ubiquitin ligases
- The mitochondrial TOM complex in neurodegenerative disease
- The molecular mechanisms underlying Kir4.1 activity in gliomas
- The role of differential splicing in the genesis of breast cancer
- Uncovering the roles of long non-coding RNAs in human bowel cancer
- Understanding malaria infection dynamics
- Understanding the function of the E3 ligase Parkin in Parkinson’s disease
- Understanding the molecular basis of chromosome instability in gastric cancer
- Utilising pre-clinical models to discover novel therapies for tuberculosis
- School resources
- Frequently asked questions
- Student profiles
- Student achievements
- Student association
- News
- Donate
- Online donation
- Ways to support
- Support outcomes
- Supporter stories
- Rotarians against breast cancer
- A partnership to improve treatments for cancer patients
- 20 years of cancer research support from the Helpman family
- A generous gift from a cancer survivor
- A gift to support excellence in Australian medical research
- An enduring friendship
- Anonymous donor helps bridge the 'valley of death'
- Renewed support for HIV eradication project
- Searching for solutions to muscular dystrophy
- Supporting research into better treatments for colon cancer
- Taking a single cell focus with the DROP-seq
- WEHI.TV
Type 1 diabetes

Type 1 diabetes occurs when the immune system attacks and destroys the beta cells in the pancreas that produce the hormone insulin. Without insulin, the level of the sugar glucose in the blood cannot be controlled.
Type 1 diabetes is a serious lifelong health condition. Our type 1 diabetes researchers are discovering how harmful immune responses damage the insulin-producing cells. This is leading to new ways to prevent and treat type 1 diabetes.
Our type 1 diabetes research
Our researchers are working to improve the prevention and treatment of type 1 diabetes. Their goals are to:
- Understand why immune cells attack insulin-producing cells.
- Develop and trial new ways to prevent type 1 diabetes.
- Develop strategies to regenerate insulin-producing cells from stem cells as a cure for type 1 diabetes.
- Improve the success of pancreas transplantation as a cure for type 1 diabetes.
What is type 1 diabetes?
The amount of glucose in the blood is normally tightly controlled. But in diabetes blood glucose levels are abnormally high.
The hormone insulin normally reduces blood glucose levels and is produced by cells in the pancreas called ‘beta cells’. However in type 1 diabetes there is a misdirected ‘autoimmune’ reaction to the insulin-producing beta cells in the pancreas, which leads to insufficient insulin being produced. Without insulin, high levels of glucose accumulate in the blood.
The immune system protects our body from invading microbes. There are normally many safeguards that prevent it from attacking the body’s own tissues. In type 1 diabetes, these safeguards fail, and immune cells specifically destroy beta cells.
Type 1 diabetes is the most common chronic (long-term) childhood illness in Australia. More than 120,000 Australians have type 1 diabetes. The incidence of type 1 diabetes in Australia has increased in the past 30 years.
Most people with type 1 diabetes are diagnosed as children or young adults. Even with a lifetime of the best available care, they are at increased risk of serious complications such as
- Kidney disease (diabetic nephropathy)
- Eye disease and blindness (diabetic retinopathy)
- Nerve damage (diabetic neuropathy)
- Damage to blood vessels, which together with nerve damage can lead to serious problems in the hands and feet
- Heart disease and stroke
Risk factors for type 1 diabetes
Type 1 diabetes is caused by a combination of genetic risk and environmental factors. Our researchers have shown that changes in our environment have contributed to the increase in the incidence of type 1 diabetes in the past few decades.
Many environmental factors have been proposed to trigger or promote type 1 diabetes. These include infections, diet and weight gain.
Known risk factors for type 1 diabetes include:
- Having other autoimmune or inflammatory diseases such as coeliac disease or autoimmune thyroid disease. These conditions all involve aberrant immune responses.
- Having a parent or sibling with type 1 diabetes or other autoimmune diseases. One in five Australians diagnosed with type 1 diabetes have a family history of the condition.
- Living at higher latitudes: the incidence of type 1 diabetes is increased in populations who live furthest from the equator. This may be partly genetic. It may also be related to environmental factors such as vitamin D deficiency and hygiene.
How is type 1 diabetes treated?
Almost all people with type 1 diabetes rely on insulin injections for their entire lives. They must closely monitor their blood glucose levels. When blood glucose rises, such as after a meal, an appropriate insulin dose is calculated and injected. Insulin is available in ‘slow acting’ and ‘fast acting’ forms. These can aid the smoother control of blood glucose levels.
There is no orally available (tablet) form of insulin. Insulin can only be given by injection, such as with a syringe. Recently, small, attachable insulin pumps have been introduced instead of multiple daily injections. Insulin pumps may control blood glucose better by providing a more steady release of insulin into the body.
The only cure for type 1 diabetes is transplantation or regeneration of insulin-producing cells.
Transplantation of the whole pancreas or the parts of the pancreas containing insulin-secreting beta cells can be performed. It is limited by a shortage of organ donors, and the need for life-long immune suppression to prevent transplant rejection. Thus, transplantation is restricted to people with poorly controlled diabetes and serious complications.
Our researchers have shown that the pancreas contains stem cells that can be transformed into beta cells. Their hope is that it may one day be possible to cure type 1 diabetes by stimulating the regrowth of beta cells. This would depend on stifling the immune cells that originally destroyed the beta cells.
Diabetes Australia has more detailed information about diabetes treatment.
Type 1 diabetes ‘vaccine’
Our research into how immune cells attack insulin-producing cells has led to a new strategy to prevent type 1 diabetes. A nasal insulin ‘vaccine’ developed by our researchers has shown promise in clinical trials for preventing the development of type 1 diabetes.
Researchers:
Super Content:
A five-year international trial has found that type 1 diabetes can be delayed by an immune therapy.
The therapy, teplizumab, delayed the onset of diabetes in participants by two years.
A drop in the number of young children diagnosed with type 1 diabetes could be associated with the introduction of routine rotavirus vaccination of Australian infants.
Australia's largest study into the causes of type 1 diabetes will track women and children from early pregnancy to three years of age.
The JDRF Lifetime Research Achievement Award recognises the long-standing nature and high quality of contributions of the very best Australian researchers who have steered global directions of type 1 diabetes research.
A landmark discovery about how insulin docks on cells could help in the development of improved types of insulin for treating both type 1 and type 2 diabetes.






